Immune therapy in GI malignancies: A review

Journal of Clinical Oncology

Volumn 33, Issue 16, 2015, Pages 1745-1753

  Wang, Judy ^a   Reiss, Kim A ^a   Khatri, Rina ^a   Jaffee, Elizabeth ^a   Laheru, Dan ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMS 936559; CD3 ANTIGEN; CETUXIMAB; CHIMERIC ANTIGEN RECEPTOR; CP 870893; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEMCITABINE; IPILIMUMAB; MGD 007; NIVOLUMAB; PANITUMUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; RAMUCIRUMAB; TRASTUZUMAB; TUMOR VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; ANTIBODY; AUTACOID; CANCER VACCINE;

ADOPTIVE TRANSFER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL TRANSFER; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; GENE FUNCTION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MICROBIOME; ONCOGENE; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STOMACH CANCER; STROMA; ADOPTIVE IMMUNOTHERAPY; ANIMAL; GASTROINTESTINAL NEOPLASMS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES; CANCER VACCINES; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INFLAMMATION MEDIATORS; LYMPHOCYTES, TUMOR-INFILTRATING; ONCOGENES; RISK FACTORS; TREATMENT OUTCOME; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84937112293     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.60.7879     Document Type: Review

References (65)

1. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014
2. Elkord E, Hawkins RE, Stern PL: Immunotherapy for gastrointestinal cancer: Current status and strategies for improving efficacy. Expert Opin Biol Ther 8:385-395, 2008
3. Mocellin S: New strategies to improve the efficacy of colorectal cancer vaccines: From bench to bedside. Curr Opin Investig Drugs 7:1052-1061, 2006
4. Schwabe RF, Jobin C: The microbiome and cancer. Nat Rev Cancer 13:800-812, 2013
5. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
6. Hingorani SR, Petricoin EF, Maitra A, et al: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437-450, 2003
7. Hingorani SR, Wang L, Multani AS, et al: Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469-483, 2005
8. Nomi T, Sho M, Akahori T, et al: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13:2151-2157, 2007
9. Gao Q, Wang XY, Qiu SJ, et al: Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15: 971-979, 2009
10. Martínez-Bosch N, Fernández-Barrena MG, Moreno M, et al: Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedge-hog signaling activation. Cancer Res 74:3512-3524, 2014
11. Kobayashi N, Kubota K, Kato S, et al: FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. Pancreatology 10:631-640, 2010
12. Brandacher G, Perathoner A, Ladurner R, et al: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: Effect on tumor-infiltrating T cells. Clin Cancer Res 12:1144-1151, 2006
13. Chatterjee S, Behnam Azad B, Nimmagadda S, et al: The intricate role of CXCR4 in cancer. Adv Cancer Res 124:31-82, 2014
14. Feig C, Jones JO, Kraman M, et al: Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 110:20212-20217, 2013
15. Maitra A, Hruban RH: Pancreatic cancer. Annu Rev Pathol 3:157-188, 2008
16. Coussens LM, Werb Z: Inflammation and cancer. Nature 420:860-867, 2002
17. Ghiringhelli F, Ménard C, Terme M, et al: CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202:1075-1085, 2005
18. Waghray M, Yalamanchili M, di Magliano MP, et al: Deciphering the role of stroma in pancreatic cancer. Curr Opin Gastroenterol 29:537-543, 2013
19. Haqq J, Howells LM, Garcea G, et al: Pancreatic stellate cells and pancreas cancer: Current perspectives and future strategies. Eur J Cancer 50:2570-2582, 2014
20. Olive KP, Jacobetz MA, Davidson CJ, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457-1461, 2009
21. Micke P, Ostman A: Exploring the tumour environment: Cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9:1217-1233, 2005
22. Feig C, Gopinathan A, Neesse A, et al: The pancreas cancer microenvironment. Clin Cancer Res 18:4266-4276, 2012
23. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331:1565-1570, 2011
24. Vonderheide RH, Bayne LJ: Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol 25:200-205, 2013
25. Sideras K, Braat H, Kwekkeboom J, et al: Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev 40:513-522, 2014
26. Quante M, Wang TC: Inflammation and stem cells in gastrointestinal carcinogenesis. Physiology (Bethesda) 23:350-359, 2008
27. Topalian SL, Drake CG, Pardoll DM: Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24:207-212, 2012
28. Callahan MK, Wolchok JD: At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 94:41-53, 2013
29. Blank C, Gajewski TF, Mackensen A: Interaction of PD-L1 on tumor cells with PD-1 on tumorspecific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy. Cancer Immunol Immunother 54:307-314, 2005
30. Vonderheide RH, Bajor DL, Winograd R, et al: CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother 62:949-954, 2013
31. Schaer DA, Hirschhorn-Cymerman D, Wolchok JD, et al: Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer 2:7, 2014
32. Moran AE, Kovacsovics-Bankowski M, Weinberg AD: The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 25:230-237, 2013
33. Yamamoto T, Yanagimoto H, Satoi S, et al: Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas 41:409-415, 2012
34. Gabitass RF, Annels NE, Stocken DD, et al: Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 60:1419-1430, 2011
35. Clark CE, Hingorani SR, Mick R, et al: Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67:9518-9527, 2007
36. Marshall JL, Gulley JL, Arlen PM, et al: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23:720-731, 2005
37. Morse MA, Niedzwiecki D, Marshall JL, et al: A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 258:879-886, 2013
38. Le DT, Lutz E, Uram JN, et al: Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 36:382-389, 2013
39. Le DT, Brockstedt DG, Nir-Paz R, et al: A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clin Cancer Res 18:858-868, 2012
40. Le DT, Wang-Gilliam A, Picozzi V, et al: Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33:1325-1333, 2015
41. Hardacre JM, Mulcahy M, Small W, et al: Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: A phase 2 study. J Gastrointest Surg 17:94-100, 2013
42. Beatty GL, Torigian DA, Chiorean EG, et al: A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 19:6286-6295, 2013
43. Royal RE, Levy C, Turner K, et al: Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33:828-833, 2010
44. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
45. Muro K, Bang Y, Shankaran V, et al: A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients with advanced gastric cancer. European Society for Medical Oncology 2014 Congress, Madrid, Spain, September 26-30, 2014 (abstr LBA15)
46. Tran E, Turcotte S, Gros A, et al: Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344:641-645, 2014
47. Gomez-Martín C, Lopez-Rios F, Aparicio J, et al: A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond. Cancer Lett 351:30-40, 2014
48. Bilusic M, Heery CR, Arlen PM, et al: Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother 63:225-234, 2014
49. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
50. Jaffee EM, Hruban RH, Biedrzycki B, et al: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol 19:145-156, 2001
51. Lutz E, Yeo CJ, Lillemoe KD, et al: A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: A phase II trial of safety, efficacy, and immune activation. Ann Surg 253:328-335, 2011
52. Laheru D, Lutz E, Burke J, et al: Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation. Clin Cancer Res 14:1455-1463, 2008
53. Thomas AM, Santarsiero LM, Lutz ER, et al: Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 200:297-306, 2004
54. Pastan I, Hassan R: Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 74:2907-2912, 2014
55. Bayne LJ, Beatty GL, Jhala N, et al: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21:822-835, 2012
56. Pylayeva-Gupta Y, Lee KE, Hajdu CH, et al: Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21:836-847, 2012
57. Lutz ER, Wu AA, Bigelow E, et al: Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2:616-631, 2014
58. Vonderheide RH, Flaherty KT, Khalil M, et al: Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876-883, 2007
59. O'Mahony D, Morris JC, Quinn C, et al: A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 13:958-964, 2007
60. Kim WK, Park M, Kim YJ, et al: Identification and selective degradation of neopeptide-containing truncated mutant proteins in the tumors with high microsatellite instability. Clin Cancer Res 19:3369-3382, 2013
61. Williams AS, Huang WY: The analysis of microsatellite instability in extracolonic gastrointestinal malignancy. Pathology 45:540-552, 2013
62. Ogino S, Nosho K, Irahara N, et al: Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 15:6412-6420, 2009
63. Nosho K, Baba Y, Tanaka N, et al: Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: Cohort study and literature review. J Pathol 222:350-366, 2010
64. Maus MV, Grupp SA, Porter DL, et al: Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123:2625-2635, 2014
65. Morgan RA, Yang JC, Kitano M, et al: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843-851, 2010